Clinical trials: Fat; Liver
Nonalcoholic Fatty Liver Disease
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.
- Trial name
- NCT02029586
- Testing
- MB12066 200mg
- Where
- 10 sites in South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males
1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2.
- Trial name
- NCT06308861
- Testing
- Single administration Amg dose Group, Single administration Bmg dose Group, Single administration Cmg dose Group
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic
Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial
The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic, Overweight (BMI > 25)
- Trial name
- NCT07193927
- Testing
- Lactiplantibacillus plantarum Probiotic Mixture
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- AB Biotics, SA
Nonalcoholic Steatohepatitis (NASH)
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of IMM-H014 on fasted condition, and characterize PK of IMM-H014 on an empty stomach (fasted condition) and…
- Trial name
- NCT06216041
- Testing
- IMM-H014, IMM-H014 ( FE)
- Where
- China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
NASH, MASH
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Trial name
- HERALD (NCT06342947)
- Testing
- ALG-055009
- Where
- 40 sites in United States
- Volunteers
- 102 people
- Sponsor
- Aligos Therapeutics
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05877547
- Testing
- Efinopegdutide, Semaglutide
- Where
- 175 sites in United States, Austria and 24 more
- Volunteers
- 381 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonalcoholic Steatohepatitis (NASH)
Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
The Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Food Effect Study of HEC96719 in Healthy Subjects
- Trial name
- NCT04546984
- Testing
- HEC96719
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Fatty Liver
A Study of JNJ-75220795 in Japanese Participants
The purpose of this study is to assess the safety and tolerability of single subcutaneous (SC) dose of JNJ-75220795 in Japanese participants.
- Trial name
- NCT05039710
- Testing
- JNJ-75220795
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Janssen Pharmaceutical K.K.
Non Alcoholic Fatty Liver Disease
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
Sidekick Health has developed a digital behavioral change program (SK-241) specifically designed for people with metabolic derangements and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05426382
- Testing
- A digital care solution for patients with NAFLD
- Where
- 2 sites in Iceland
- Volunteers
- 38 people
- Sponsor
- Sidekick Health
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease…
- Trial name
- LFQ (NCT04657523)
- Testing
- Investigational Liver Fat Quantification Software
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
NASH - Nonalcoholic Steatohepatitis, NAFLD
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT03291249
- Testing
- Foralumab, Omeprazole 20mg
- Sponsor
- Tiziana Life Sciences LTD
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, NAFLD
Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers
This study is to evaluate the effect of food on the pharmacokinetics of a single dose of ASC41 tablet in healthy volunteers, comparing fasting and postprandial pharmacokinetic parameters of Tmax, Cmax, AUC0-t, AUC0-∞.
- Conditions
- Healthy, NAFLD, Hyperlipidemia
- Trial name
- NCT04692025
- Testing
- ASC41 tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Nonalcoholic Steatohepatitis
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
- Trial name
- AURORA (NCT03028740)
- Testing
- Cenicriviroc
- Where
- 346 sites in United States, Australia and 26 more
- Volunteers
- 1,778 people
- Sponsor
- Tobira Therapeutics, Inc.
NASH (Non-Alcoholic Steatohepatitis)
Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis
VENS is a multicenter, randomized, double-masked, placebo parallel controlled trial to evaluate the efficacy and safety of treatment with vitamin E softgel in non diabetic adults with NASH compared to treatment with placebo in…
- Trial name
- NCT02962297
- Testing
- Vitamin E softgel
- Where
- 15 sites in China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Medicine Co., Ltd.
Hepatic Impairment, Healthy Participants
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919
- Trial name
- NCT04193436
- Testing
- PF-06835919 25 mg
- Where
- 3 sites in Belgium, Czechia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type II, Fatty Liver
Study of INT-747 in Patients With Diabetes and Presumed NAFLD
The primary objectives of this study are to assess, in patients with Type 2 diabetes mellitus (DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following: The safety and tolerability of multiple doses of INT 747…
- Trial name
- NCT00501592
- Testing
- INT-747
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Intercept Pharmaceuticals
Nonalcoholic Steatohepatitis, Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
- Trial name
- NASH (NCT05011305)
- Testing
- Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg
- Where
- 129 sites in United States, Argentina and 2 more
- Volunteers
- 189 people
- Sponsor
- Zydus Therapeutics Inc.